10mg
PT-141 10mg per vial
Ideal For
Patients seeking enhanced sexual desire, improved arousal response, and support for sexual wellness through a centrally-acting peptide mechanism.
Melanocortin Agonist
Sexual Wellness & Arousal Enhancement
PT-141 is a melanocortin receptor agonist that supports sexual arousal and desire in both men and women by activating pathways in the central nervous system—offering a unique approach to sexual wellness that works through the brain rather than vascular mechanisms.
10mg
Per Vial
SC/IM
Administration
MC4R
Receptor Target
22+
BHRC Locations
Available Option
A melanocortin receptor agonist peptide designed to support sexual arousal and desire through central nervous system activation.
PT-141 10mg per vial
Ideal For
Patients seeking enhanced sexual desire, improved arousal response, and support for sexual wellness through a centrally-acting peptide mechanism.
The Science
PT-141, also known as Bremelanotide, is a synthetic peptide that acts as a melanocortin receptor agonist with a specific affinity for MC4R receptors in the brain. Unlike traditional treatments that focus on vascular mechanisms, PT-141 works through the central nervous system to influence sexual desire and arousal.
Originally developed from the peptide Melanotan II, PT-141 was refined to specifically target sexual function without the unwanted side effects. It activates melanocortin receptors involved in sexual motivation, desire, and arousal—making it effective for both men and women experiencing low libido or arousal difficulties.
Clinical research led to FDA approval of bremelanotide (Vyleesi) for one indication in premenopausal women; BHRC's 10mg vial is compounded and other uses are off-label. At BHRC, our physicians use PT-141 as part of comprehensive sexual wellness protocols, customized to each patient's unique needs and health profile.
Book a Consultation

How It Works
PT-141 activates specific melanocortin receptors in the brain, triggering pathways that enhance sexual desire and arousal through central nervous system modulation.
Binds to melanocortin-4 receptors in the hypothalamus and other brain regions involved in sexual behavior, triggering the cascade that leads to increased desire and arousal.
Works through the central nervous system rather than peripheral vascular mechanisms—addressing sexual desire at its neurological source for both psychological and physiological effects.
Supports natural sexual response by enhancing neurological pathways associated with arousal, desire, and sexual motivation—effective for a wide range of sexual wellness concerns.
Clinical Benefits
Supports increased libido and sexual motivation by activating brain pathways responsible for desire—addressing low libido at its neurological source.
Enhances the natural physiological arousal response in both men and women—supporting better sexual performance and satisfaction through CNS activation.
Studied in both men and women; the FDA-approved brand is indicated only for premenopausal women, and use in men is off-label.
Works through brain pathways rather than vascular mechanisms, which sets it apart from erectile dysfunction medications.
Effects typically begin within 45-60 minutes of administration and can last several hours—allowing for spontaneous intimate encounters with proper planning.
Supports improved intimacy and relationship satisfaction by addressing underlying desire and arousal concerns—enhancing overall sexual wellness and quality of life.

Your Journey
Meet with a BHRC physician to discuss your sexual wellness goals and determine if PT-141 is appropriate for your needs.
Complete comprehensive lab testing to rule out underlying conditions and assess treatment candidacy.
Receive your personalized PT-141 protocol with clear dosing instructions, administration guidance, and timing recommendations.
Regular check-ins to assess response, optimize dosing, and adjust your protocol for best results and satisfaction.

Safety Profile
At BHRC, patient safety is paramount. PT-141 is administered only after thorough medical evaluation, comprehensive screening, and confirmation of treatment candidacy by our experienced physicians specializing in sexual wellness.
22+
BHRC locations providing comprehensive sexual wellness care
Physician
Supervised treatment protocols and ongoing monitoring
Quality
Verified sourcing and pharmaceutical-grade peptide standards

At a glance

Your plan
Low desire has many causes: relationship stress, depression and anxiety, medications such as some antidepressants and blood pressure drugs, hormonal changes, pain during sex and medical conditions. The BHRC clinical team asks about each of these, because a drug that acts on desire will not fix a cause that sits elsewhere, and some causes need their own treatment first. You can bring a partner to the visit if you want to, but you do not have to; some people find it easier to talk about this alone first.
Bremelanotide can raise blood pressure briefly after a dose, so your blood pressure is measured and your heart history reviewed. Uncontrolled high blood pressure or known cardiovascular disease rules it out at BHRC. Relevant labs, such as hormone levels when symptoms suggest a hormonal cause, are ordered as needed.
If PT-141 is a reasonable fit, the provider explains the difference between the FDA-approved autoinjector and BHRC's compounded vial, including that use outside the approved label is off-label. You leave with written instructions on timing, storage, injection technique and how far apart doses must be. The dose is set by the provider.
Many people are advised to try the first dose at a calm time at home, not before an important evening, so they know how their body reacts, particularly to nausea and flushing. The provider may suggest how to manage nausea if it occurs. Avoiding a heavy meal or alcohol around the first dose is a common practical tip, and you should not drive until you know how you react.
After a few uses, the clinic reviews whether desire or arousal changed in a way that matters to you, any side effects, and a blood pressure check. If there was no meaningful benefit, the honest recommendation is usually to stop rather than escalate. If there was a partial benefit, the provider may adjust timing before considering any change in dose, because timing relative to activity is often what people get wrong first.
Timeline
In the approved product's trials, effects are designed to be used ahead of sexual activity; nausea, flushing and headache, when they happen, usually appear within the first hours and pass.
The response is variable. Some people notice increased interest or arousal, some notice side effects only, and some notice nothing.
Enough experience to judge whether it is worth continuing. The approved label advises stopping if there is no improvement after eight weeks.
On-demand use continues only if it is helping and side effects stay acceptable, with periodic blood pressure checks and a watch for skin darkening.
Compare
| Option | How it acts | Use pattern | Status |
|---|---|---|---|
| PT-141 10mg vial (this page) | Brain melanocortin receptors (desire and arousal) | On demand, injected | Compounded; not FDA-approved |
| Vyleesi (bremelanotide autoinjector) | Same molecule | On demand, injected | FDA-approved for HSDD in premenopausal women only |
| PDE5 inhibitors (sildenafil, tadalafil) | Blood flow to erectile tissue | On demand or daily, oral | FDA-approved for erectile dysfunction in men |
| Kisspeptin | Reproductive hormone axis | Clinic-guided trial | Not FDA-approved; FDA 503A Category 2 |
| Sex therapy or couples counseling | Psychological and relational factors | Sessions | Standard care |
Is it right for you?
Monitoring
Blood pressure is the main safety marker. The approved label describes a transient rise in blood pressure and a small fall in heart rate after each dose, peaking two to four hours later and usually resolving within 12 hours, and an analysis of the development program advised caution in anyone at cardiovascular risk. BHRC checks blood pressure at the consult and at follow-up and asks you to report headaches, chest discomfort or palpitations after a dose.
Nausea is the most common reason people stop. The Vyleesi label reports nausea in 40% of patients in the phase 3 program, with 8% stopping early because of it, and notes that it improved for most people with the second dose. Flushing and headache are the next most common effects. If nausea is severe or you vomit, call the clinic before using it again.
Skin darkening, especially on the face, gums or breasts, has been reported with repeated use, and the Vyleesi label reports it in about 1% of patients using up to eight doses a month, with a higher risk with daily dosing and in people with darker skin; in some cases it did not resolve. Report any new pigmentation. Because this is a melanocortin drug, BHRC also asks about moles and skin cancer history before prescribing and at reviews.
Regulatory status
Regulatory status: Bremelanotide is FDA-approved under the brand name Vyleesi, an autoinjector indicated only for premenopausal women with acquired, generalized hypoactive sexual desire disorder; the label states it is not indicated for postmenopausal women, men, or to enhance sexual performance. The PT-141 10mg vial on this page is a compounded preparation; compounded drugs are not FDA-approved and FDA does not review them for safety, effectiveness or quality. Use outside the approved label is off-label. BHRC prescribes PT-141 only after a consultation, a blood pressure check and a medication review with a licensed provider. This page does not claim that PT-141 treats, cures or prevents any sexual or medical condition beyond the approved label. Prepared by the BHRC team from FDA and PubMed sources.
Before you book
PT-141, or bremelanotide, is a synthetic peptide related to alpha-melanocyte-stimulating hormone. It activates melanocortin receptors in the brain, especially the MC4 receptor, which is involved in sexual motivation. It does not work by increasing blood flow the way erectile dysfunction pills do, which is why it is described as acting on desire rather than mechanics. The approved label notes that how long each dose lasts, and the ideal window for taking it, have not been fully worked out, so some trial and error with timing is normal.
The molecule is, under a specific brand and label. Bremelanotide was approved in 2019 as Vyleesi for premenopausal women with acquired, generalized hypoactive sexual desire disorder. The approved label says it is not indicated for postmenopausal women, men, or to enhance sexual performance. BHRC's 10mg vial is compounded and is not FDA-approved, and any use outside that label is off-label.
There is some research. A 2008 randomized trial in men whose erectile dysfunction did not respond to sildenafil reported more positive responses with bremelanotide than placebo, along with more side effects. Bremelanotide has not been approved for men, and the evidence is far thinner than for standard erectile dysfunction treatments, which your provider will discuss as well. If erections are the main concern rather than desire, a PDE5 inhibitor or an evaluation for an underlying cause is usually the more evidence-based first step.
Two phase 3 trials involving more than 1,200 premenopausal women with HSDD found statistically significant, modest increases in sexual desire and reductions in related distress compared with placebo. Nausea, flushing and headache were more common with bremelanotide. Later subgroup analyses found similar patterns across age, weight and contraceptive use.
Your provider sets the dose and the minimum gap between doses at the consult. For general background on how PT-141 is used and how the vial is handled, see our PT-141 Dosage Guide. It is educational, not a prescription.
Cost depends on whether a compounded vial or the brand product is appropriate, how often you expect to use it, and the follow-up visit. BHRC does not post prices here; you receive a quote after the consultation. The brand autoinjector may be partly covered by some insurance plans for its approved indication, while compounded vials generally are not.
The most common are nausea, flushing, headache and injection-site reactions. Blood pressure can rise briefly after a dose. Skin darkening has been reported with repeated use. Serious reactions are uncommon in trials but anything unexpected should be reported. The label also limits use to one dose within 24 hours and no more than eight doses a month, partly to limit blood pressure effects and pigmentation risk; your plan will include a similar ceiling.
Tell your provider about everything you take. Bremelanotide can lower blood levels of oral naltrexone, which can make naltrexone less effective, and it can slow stomach emptying, which may affect some oral drugs. Blood pressure medications and antidepressants are reviewed too.
Both act on melanocortin receptors, and bremelanotide was developed from the same research line. Melanotan II has broader effects, including on skin pigment, and FDA has published serious safety concerns about compounded Melanotan II. Bremelanotide is the one with an approved product and a published safety program.
Not at BHRC. A consultation is required because blood pressure, cardiovascular history, pregnancy status and medication interactions all affect whether it is safe for you.
Selected research
The literature below is peer-reviewed background on PT-141 and the mechanisms discussed on this page, so you can read the primary sources yourself. It is not evidence of any particular outcome at BHRC, and some of it is preclinical work in animals or cells. Your provider will discuss what the evidence does and does not support for your situation.
Common Questions
PT-141 (Bremelanotide) is a melanocortin receptor agonist peptide that enhances sexual desire and arousal by activating MC4R receptors in the brain. Unlike traditional treatments, it works through the central nervous system to address low libido in both men and women.
PT-141 is administered via subcutaneous injection, typically 45-60 minutes before anticipated sexual activity. Your BHRC physician will provide detailed injection training and dosing instructions based on your individual protocol.
PT-141 supports enhanced sexual desire, improved arousal response, and better sexual satisfaction. It has been studied in both men and women and works through central pathways. Individual results vary.
Ideal candidates are adults experiencing low libido, reduced sexual desire, or arousal difficulties not fully addressed by other treatments. A BHRC physician will evaluate your medical history, sexual health concerns, and overall wellness to determine if PT-141 is appropriate for you.
Common side effects may include temporary flushing, nausea, or headache. Some patients experience increased blood pressure or skin darkening with prolonged use. Your BHRC physician will discuss all potential side effects, contraindications, and monitoring protocols during your consultation.
PT-141 typically begins working within 45-60 minutes of administration, with effects lasting several hours. For best results, patients should plan administration timing based on anticipated activity. Response varies by individual, and your physician will help optimize timing and dosing for your needs.
Get Started
Schedule a consultation with our medical team to learn if PT-141 peptide therapy is right for your sexual wellness journey.
"*" indicates required fields

Or call us directly: +1 213-325-3373
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary. Consult with a qualified healthcare professional before beginning any supplementation program. PT-141 is available only through licensed medical providers. BHRC physicians will evaluate your candidacy based on comprehensive medical assessment and health screening.